You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》摩通下調再鼎醫藥(ZLAB.US)目標價至70美元 評級「增持」
摩根大通發表研報指,近日交流時再鼎醫藥(09688.HK)(ZLAB.US)首次提出至2025年底實現盈利的長期指引,主要依賴三款核心產品Zejula、Optune及efgartigimod,以及其他在研項目的潛在增長。 該行表示,雖然見到公司至2025年第四季實現盈利的可能,但與市場相比,摩通的內部預測仍相對保守,當中較為看好Zejula及efgartigimod的銷售前景 ,又指公司2024至2025年上的研發及營銷開支增幅料達到中單位數百分比,同時關注預付款情況。 摩通對再鼎醫藥給予「增持」評級,預期公司可實現峰值銷售額30億美元以上,基於對核心管道資產的風險調整後收入及支出預測,將美股目標價由79美元下調至70美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account